Pipeline

EU101
Indication Solid tumor Target /Drug class Anti-human 4-1BB mAb Development Stage Phase I/II study
Summary
  • Anti-human 4-1BB monoclonal therapeutic antibody
  • Better efficacy for tumor clearance than competitors in vivo
  • Accelerates infiltration of lymphocyte into tumor tissue
  • Promising platform technology for combination therapy with immune checkpoint inhibitors
In vitro/in vivo Efficacy
Mode of Action ; Activation of cytotoxic CD8+ T cell